The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IDXG | -67.93% | -77.2% | -25.6% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +499% |
Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.23M | -23.3% |
| Gross Profit | $5.28M | -29.0% |
| Gross Margin | 57.15% | -4.6% |
| Market Cap | $3.32M | -34.1% |
| Market Cap / Employee | $0.03M | 0.0% |
| Employees | 111 | 2.8% |
| Net Income | -$0.53M | -125.0% |
| EBITDA | -$0.27M | -111.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.50M | -75.1% |
| Accounts Receivable | $7.23M | 16.5% |
| Inventory | 1 | -21.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.97M | -24.3% |
| Short Term Debt | $2.18M | -69.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 35.15% | 14.4% |
| Return On Invested Capital | -149.62% | -126.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.32M | -73.6% |
| Operating Free Cash Flow | $0.52M | -63.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 1.68 | 2.27 | 0.83 | 1.43 | -20.82% |
| Price to Book | -0.13 | -0.21 | -1.87 | -5.70 | 6825.88% |
| Price to Sales | 0.18 | 0.25 | 0.54 | 0.07 | -39.90% |
| Price to Tangible Book Value | -0.13 | -0.21 | -1.87 | -5.70 | 6825.76% |
| Price to Free Cash Flow TTM | 2.14 | 3.15 | 5.12 | 0.79 | -52.09% |
| Enterprise Value to EBITDA | 28.45 | 7.17 | 14.41 | -22.18 | -193.57% |
| Free Cash Flow Yield | 46.6% | 31.7% | 19.5% | 126.7% | 108.74% |
| Total Debt | $7.18M | $5.86M | $4.24M | $3.15M | -62.43% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
